T. Rowe Price Investment Management, Inc. Macrogenics Inc Transaction History

T. Rowe Price Investment Management, Inc.

  • $163 Billion
  • Q1 2024

A detailed history of T. Rowe Price Investment Management, Inc. transactions in Macrogenics Inc stock. As of the latest transaction made, T. Rowe Price Investment Management, Inc. holds 2,767,034 shares of MGNX stock, worth $11.8 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
2,767,034
Previous 5,639,994 50.94%
Holding current value
$11.8 Million
Previous $54.3 Million 24.93%
% of portfolio
0.02%
Previous 0.04%

Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024
SELL
$9.77 - $21.47 $28.1 Million - $61.7 Million
-2,872,960 Reduced 50.94%
2,767,034 $40.7 Million
Q4 2023

Feb 14, 2024
BUY
$4.48 - $10.11 $663,228 - $1.5 Million
148,042 Added 2.7%
5,639,994 $54.3 Million
Q3 2023

Nov 14, 2023
BUY
$4.48 - $6.19 $131,264 - $181,367
29,300 Added 0.54%
5,491,952 $25.6 Million
Q2 2023

Aug 14, 2023
BUY
$4.62 - $7.54 $11.8 Million - $19.2 Million
2,549,247 Added 87.5%
5,462,652 $29.2 Million
Q1 2023

May 15, 2023
BUY
$4.82 - $7.24 $176,783 - $265,541
36,677 Added 1.27%
2,913,405 $20.9 Million
Q4 2022

Feb 14, 2023
SELL
$5.62 - $6.98 $29,679 - $36,861
-5,281 Reduced 0.18%
2,876,728 $19.3 Million
Q3 2022

Nov 14, 2022
BUY
$3.01 - $5.22 $8.67 Million - $15 Million
2,882,009 New
2,882,009 $9.97 Million

Others Institutions Holding MGNX

# of Institutions
170
Shares Held
62.4M
Call Options Held
819K
Put Options Held
79.4K
View Full List

About MACROGENICS INC

MGNX Quotes by TradingView
  • Ticker MGNX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 61,458,800
  • Market Cap $261M
  • Description
  • MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...
More about MGNX
Track This Portfolio

Track T. Rowe Price Investment Management, Inc. Portfolio

Follow T. Rowe Price Investment Management, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of T. Rowe Price Investment Management, Inc., based on Form 13F filings with the SEC.

News

Stay updated on T. Rowe Price Investment Management, Inc. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email